Introduction
============

Initially, search for the possible cellular substrate of mood disorder pathology had focused on neurons ([@B59], [@B60]; [@B21],[@B22], [@B20]; [@B51]). However, during the last years a wave of information appeared to suggest that glial cells prominently, and in many ways, contribute to brain structural and functional changes in mood disorders. In numerous histological postmortem investigations both significantly reduced ([@B56]; [@B59]; [@B21],[@B22]; [@B36]; [@B79]; [@B61]; [@B1]; [@B34]) and increased ([@B24]; [@B55]; [@B49]) glial cell numbers and numerical densities have been observed in prefrontal cortex areas and limbic regions. In addition, characteristic changes in gene expression patterns and metabolic pathways of glial cells have been found in affective disorders (reviewed in [@B5]; [@B74]; [@B55]; [@B30]; [@B68]; [@B10]). Of note, each of the three glial cell classes (i.e., ACs, OLs, and microglia) appears to confer its unique contribution to the pathophysiology of affective disorders. Moreover, their impact may be different in MDD ([@B81]) and in BD, ([@B66]; [@B27]). In this context, much attention has been paid to the possible role of ACs in MDD and BD pathology. Being the most prevalent cell type in the human brain, ACs serve a wide range of different functions in the CNS. They play important roles in synaptic transmission, control of neuronal metabolism, sensing of brain microenvironment, maintenance of blood-brain barrier integrity, brain defense and inflammatory processes ([@B73]; [@B76]). Since synaptic, metabolic and inflammatory dysregulation are reported in MDD and BD ([@B37]; [@B71]; [@B43]; [@B29]; [@B50]; and others), AC abnormalities may be implicated in these disorders. ACs exert influence on cerebral information processing mainly in two ways: (1) they release, by exocytosis, gliotransmitters (glutamate, [D]{.smallcaps}-serine, GABA and ATP, [@B64]), which facilitate the communication between neurons and neuron-glia crosstalk, and (2) they remove glutamate from extracellular space and provide glutamatergic and GABAergic neurons with glutamine, which they synthesize from glutamate, ammonia and ATP ([@B2]). Theoretically, impaired release of gliotransmitters ([@B80]) and/or compromised glutamate uptake and recycling by ACs might significantly contribute to anomalies of glutamatergic (and, most probably, GABAergic) neurotransmission reported in MDD and BD (for reviews, see [@B83]; [@B15]; [@B33]; [@B65]; [@B11]; [@B28]; [@B29]; [@B3]; [@B57]). However, while knowledge about the possible impact of gliotransmitters on mood disorder pathology is still fragmentary ([@B31]), there is some good evidence in favor of impaired AC-related glutamate-glutamine cycling as an important contributing factor in affective disorders (reviewed in detail by [@B11] and [@B62]). Due to its central position in the glutamate--glutamine--GABA cycle, the glutamine-synthesizing enzyme GS (aka glutamate-ammonia ligase, EC 6.3.1.2) came early into focus of research, and a number of papers have meanwhile been published about alterations in GS in MDD and BD. In subjects with MDD a majority of studies show a decrease of cerebral GS. The expression of GS mRNA was reported to be down-regulated in the prefrontal cortex, the premotor cortex, and the amygdala of depressed suicide victims but not in suicide completers without depression ([@B19]; [@B69]), whereas GS protein was found to be reduced in the anterior cingulate cortex and the orbitofrontal cortex ([@B19]; [@B6]; [@B53]; [@B62]). However, no alterations in cortical GS of MDD subjects were found by others ([@B78]). The implication of GS for BD is less well explored, and the sparse data are inconsistent. GS expression was reported unchanged ([@B78]) or decreased ([@B19]) in the prefrontal cortex of bipolar subjects. Remarkably, all but one ([@B78]) studies on GS expression in mood disorders used biochemical techniques. Thus, little attention has yet been paid to the type of GS-expressing cells, although there is evidence that GS can also be detected in extra-astroglial localizations \[i.e., in numerous OLs and even in some neurons ([@B75]; [@B40]; [@B7] and others)\]. Thus, theoretically, disease-related alterations of GS expression might involve non-astroglial cells, too. We, therefore, counted GS expressing glial cells in ten different cortical and subcortical brain areas of subjects with MDD, BD, and psychically healthy controls and show herein that (1) significantly reduced densities of GS-immunoreactive glial cells occur in cortical areas of MDD, but not BD subjects and (2) these changes are restricted to GS expressing ACs, whereas GS expressing OLs are normal in mood disorders.

Materials and Methods {#s1}
=====================

Subjects
--------

All brains were obtained from the New Magdeburg brain collection. Case recruitment, acquisition of personal data, performance of autopsy, and handling of autoptic material were conducted in strict accordance with the Declaration of Helsinki, and have been approved by the responsible Ethical Committee of Magdeburg. Written consent was obtained from the next-of-kin. Information for clinical diagnoses was obtained from clinical records and/or structural interviews of physicians involved in treatment or relatives ([@B13]).

Brains of 29 human subjects with mood disorders according to DSM-IV were studied. Of these individuals 14 (8 female, 6 male; mean age: 46.9 ± 11.4 years) had suffered from a MDD and 15 (5 female, 10 male; mean age: 53.5 ± 10.4 years) had a BD. Sixteen control individuals (9 female, 7 male; mean age: 50.4 ± 11.0 years) without a history of neuropsychiatric disorder were also investigated. None of the patients or controls had a history of substance abuse or alcoholism. Neuropathological changes due to neurodegenerative or traumatic processes were ruled out by an experienced neuropathologist as previously described ([@B13]). These cases were matched with respect to age, gender, and autolysis time. The matching processes were done prior to all analyses. For demographical, clinical, and psychopharmacological details see **Tables [1](#T1){ref-type="table"}** and **[2](#T2){ref-type="table"}**. The mean daily doses of psychotropic medication taken by patients during the last 90 lifetime days were established according to the clinical files. Since our brain bank has been established about 25 years ago, patients received tricyclic antidepressants instead of selective serotonin or noradrenalin reuptake inhibitors (for detailed considerations, see [@B55]).

###### 

Demographical data of patients and controls.

  Diagnosis case            Gender                  Age (years)       Postmortem autolysis time (h)   Duration of illness/years   Cause of death
  ------------------------- ----------------------- ----------------- ------------------------------- --------------------------- ---------------------------------------
  **MDD (*n* = 14)**                                                                                                              
  1                         Male                    42                5                               n.a.                        Suicide (hanging)
  2                         Female                  39                48                              7                           Suicide (benzodiazepines overdose)
  3                         Female                  46                48                              11                          Suicide (hanging)
  4                         Female                  53                48                              n.a.                        Suicide (hanging)
  5                         Female                  63                17                              2                           Pulmonary embolism
  6                         Female                  61                70                              11                          Heart failure
  8                         Male                    35                24                              2                           Suicide (slitting of the wrists)
  9                         Male                    36                48                              1                           Suicide (hanging)
  10                        Male                    42                24                              n.a.                        Acute pancreatitis
  11                        Male                    30                24                              n.a.                        Suicide (hanging)
  12                        Female                  60                24                              1                           Suicide (hanging)
  13                        Female                  59                48                              4                           Suicide (hanging)
  14                        Female                  35                24                              n.a.                        Suicide (strangulation)
  15                        Male                    55                24                              n.a.                        Suicide (strangulation)
                            **8 Female/6 Male**     **46.9 ± 11.4**   **34.0 ± 17.6**                 **4.9 ± 4.3**               
  **BD (*n* = 15)**                                                                                                               
  16                        Male                    47                24                              9                           Suicide (stabbing)
  17                        Female                  46                4                               13                          Suicide (tablet intoxication)
  18                        Male                    42                12                              16                          Suicide (hanging)
  19                        Female                  62                72                              11                          Pulmonary embolism
  21                        Male                    39                24                              2                           Pulmonary embolism
  22                        Female                  59                72                              24                          Suicide (tablet intoxication)
  23                        Male                    39                56                              14                          Myocardial infarction
  24                        Male                    69                48                              26                          Pulmonary embolism
  25                        Male                    69                24                              18                          Heart failure, pulmonary embolism
  26                        Female                  52                24                              16                          Heart failure, pulmonary embolism
  27                        Female                  65                52                              25                          Heart failure
  28                        Male                    44                96                              6                           Trombosis after myocardial infarction
  29                        Male                    57                48                              n.a.                        Suicide (strangulation)
  30                        Male                    60                24                              5                           Suicide (strangulation)
  31                        Male                    53                24                              1                           Suicide (strangulation)
                            **5 female/10 Male**    **53.5 ± 10.4**   **40.3 ± 25.8**                 **13.3 ± 8.2**              
  **Depression**            **13 female/16 Male**   **50.3 ± 11.2**   **37.2 ± 22.1**                 **10.2 ± 8.1**              
  **Controls (*n* = 16)**                                                                                                         
  31                        Male                    56                48                              0                           Retroperitoneal hemorrhage
  34                        Female                  52                24                              0                           Heart failure, renal insufficiency
  35                        Female                  48                48                              0                           Status asthmaticus
  38                        Female                  33                72                              0                           Aortic embolism
  39                        Female                  50                72                              0                           Ruptured aortic aneurysm
  40                        Male                    40                96                              0                           Myocardial infarction
  41                        Male                    64                36                              0                           Ruptured aortic aneurysm
  42                        Female                  48                26                              0                           Pulmonary embolism
  43                        Male                    56                24                              0                           Myocardial infarction
  44                        Female                  65                24                              0                           Heart failure
  45                        Female                  30                48                              0                           Pulmonary embolism
  46                        Male                    63                48                              0                           Heart failure (after heart surgery)
  47                        Female                  38                24                              0                           Heart failure
  48                        Male                    54                24                              0                           Pulmonary embolism
  49                        Male                    46                24                              0                           Heart failure, cancer
  50                        Female                  63                24                              0                           Myocardial infarction
                            **9 Female/7 Male**     **50.4 ± 11.0**   **41.4 ± 22.2**                 **-**                       

###### 

Psychopharmacological treatment.

  Case                 Mean antidepressiva dose of the last days \[mg\]   Mean neuroleptics dose of the last days \[mg\]   Mean benzodiazepine dose of the last days \[mg\]   Mean carbamazepine dose of the last days \[mg\]   Mean lithium dose of the last days \[mg\]
  -------------------- -------------------------------------------------- ------------------------------------------------ -------------------------------------------------- ------------------------------------------------- -------------------------------------------
  **MDD (*n* = 14)**                                                                                                                                                                                                            
  1                    n.a.                                               n.a.                                             n.a.                                               n.a.                                              n.a.
  2                    93                                                 0                                                3                                                  0                                                 560
  3                    124                                                109                                              0                                                  0                                                 0
  4                    0                                                  0                                                0                                                  0                                                 0
  5                    50                                                 0                                                0                                                  0                                                 0
  6                    30                                                 111                                              16                                                 0                                                 0
  8                    0                                                  0                                                0                                                  0                                                 0
  9                    0                                                  0                                                0                                                  0                                                 0
  10                   200                                                200                                              n.a.                                               n.a.                                              n.a.
  11                   100                                                100                                              n.a.                                               n.a.                                              n.a.
  12                   100                                                440                                              0                                                  0                                                 0
  13                   n.a.                                               n.a.                                             n.a.                                               n.a.                                              n.a.
  14                   n.a.                                               n.a.                                             n.a.                                               n.a.                                              n.a.
  **BD (*n* = 15)**                                                                                                                                                                                                             
  16                   20                                                 0                                                0                                                  0                                                 0
  17                   133                                                327                                              3                                                  0                                                 558
  18                   95                                                 47                                               18                                                 0                                                 565
  19                   0                                                  110                                              18                                                 0                                                 0
  21                   0                                                  280                                              0                                                  0                                                 0
  22                   112                                                0                                                10                                                 600                                               0
  23                   0                                                  221                                              1                                                  0                                                 740
  24                   0                                                  0                                                7                                                  0                                                 0
  25                   0                                                  0                                                2                                                  0                                                 280
  26                   0                                                  n.a.                                             n.a.                                               n.a.                                              n.a.
  27                   93                                                 117                                              4                                                  0                                                 0
  28                   n.a.                                               n.a.                                             n.a.                                               n.a.                                              n.a.
  29                   n.a.                                               n.a.                                             n.a.                                               n.a.                                              n.a.
  30                   n.a.                                               n.a.                                             n.a.                                               n.a.                                              n.a.
  31                   150                                                200                                              0                                                  200                                               0

Tissue Processing
-----------------

Brains were removed within 4--96 h after death and fixed in toto in 8% phosphate-buffered formaldehyde for at least 2 months (pH = 7.0, *T* = 15--20°C).

Frontal and occipital poles were separated by coronal cuts 0.9 cm anterior to the genu and posterior to the splenium of the corpus callosum. After embedding of all parts of the brains in paraffin, serial coronal sections of the prefrontal and the middle blocks were cut (20 μm) and mounted. The shrinkage factor caused by fixation and embedding of the brains was calculated by a method described previously ([@B8]). The mean volume shrinkage factor for patients with affective disorders and controls was 2.21. No significant differences in the shrinkage factors among the three groups MDD, BP, and controls were found. Every 50th section was Nissl and myelin stained as described previously ([@B9]).

Glutamine Synthetase Immunohistochemistry
-----------------------------------------

For immunohistochemical stainings, whole brain sections were collected at intervals of about 0.2 cm between 1.8 and 1 cm rostral to the genu of the corpus callosum. The pACC, (Brodmann Area 32) and dorsolateral prefrontal (DLPFC, Brodmann Area 9) cortices were easily identifiable using the "Atlas of the Human Brain" by [@B48]. Sections containing the left and right sACC, Aic, (Brodmann area 14), and the NAc were selected at intervals of 0.2 cm. To immunolocalize GS, we employed a well-characterized, monospecific polyclonal antiserum generated in rabbits against human GS (Prestige Antibody HPA 007316; Lot C 81287; from Sigma--Aldrich, Munich, Germany). Since different lots of the same antibody may considerably differ with regard to their staining properties ([@B23]), we tested three different lots of the GS antiserum HPA 007316 (namely A42599, C81287, R04375). In our hands all three lots were of the same superior quality, and we decided to continue working with Lot C 81287. After dewaxing antigen demasking was carried out by boiling the sections for 4 min in 10 mM citrate buffer (pH 6.0). Thereafter, the sections were pre-incubated with methanol/H~2~O~2~ to suppress endogenous peroxidases and repeatedly washed with PBS. Subsequently, the primary GS antibody was applied at a dilution of 1:500 for 72 h at 4°C. Sections were then incubated with a biotinylated anti rabbit IgG (Amersham Bioscience, Buckinghamshire, GB), followed by the streptavidin horse radish complex for the application of the streptavidin--biotin technique (Amersham). The chromogen 3,3′-diaminobenzidine was used to visualize the reaction product. Subsequently, ammonium nickel sulfate hexahydrate was added to enhance the immunoreaction ([@B11]). For control purposes, the primary antiserum was replaced by either buffer or normal serum. Further control experiments involved the application of the GS antiserum after preabsorption with GS protein (recombinant human GS, charge number CE02; from Novoprotein, Shanghai, China) as described earlier in detail ([@B7]). When these controls were done the investigated regions did not show any specific immunostaining.

Glial Fibrillary Acidic Protein (GFAP) Immunohistochemistry
-----------------------------------------------------------

For reasons of comparison and better delineation of cortical gray matter areas sections adjacent to GS immunostained ones were immunolabeled for GFAP. A monoclonal antibody (diluted 1:100 in PBS, from DAKO) was used. The secondary antibody was an anti-mouse peroxidase (from Biozol, Eching, Germany; dilution 1:50). The working dilution was 1:2000. Visualization was as described for GS. Controls involved replacement of the primary antiserum by either buffer or normal serum.

Cell Countings
--------------

The actual section thickness after the histological procedures was 18.9 ± 1.0 μm (mean ± SD). The optical disector cell-counting method was employed. Cell countings were performed in two coronal sections per brain area under blind conditions. A counting grid was used to define a three-dimensional box within the thickness of the section as described previously ([@B9]) allowing at least 4 μM guard zones at the top and bottom of the section, and to apply a direct, three-dimensional counting method. Fifteen consecutive boxes per left and right cortical area were positioned, spanning the layers I and II, layer III, and another 15 spanning the layers IV, V, and VI, thus subdividing cortical gray matter regions into superficial and deep layers as proposed by [@B44]. To count immunostained cells in the NAc we used 15 boxes per section and hemisphere. The packing densities of glial cells are noted as the number of cells × 10^3^/mm^3^. The product of the volume and glial cell density provided the total cell number estimates. The inter-rater reliability was about 0.87. In a few cases we observed some local tissue damage in the brain region of interest. Cell counts of these particular regions were rigorously excluded from further calculations, which resulted in smaller cohorts than nominally indicated (for example, number of right NAc in MDD subjects: 12 instead of 14 cases).

Statistical Analysis
--------------------

A single-factor analysis of variance was performed using diagnostic groups as a three-level independent variable (MDD patients versus BD versus non-psychiatric controls) and measured and calculated parameters were treated as dependent variables. MANOVA was performed with diagnosis and side, ie., left and right hemisphere, as independent variables (repeated measures). Effect sizes were determined for 3-group comparisons (major depressive disorder, BD, controls). Confounding variables including whole brain volume were primarily tested on normality by use of the Kolmogorov--Smirnov test. A *post hoc* Tukey HSD test was conducted to determine which variables were significantly different from each other. Pearson correlation tests were carried out to investigate effects of postmortem delay, time of fixation, illness duration, number of illness episodes, and psychotropic medication (i.e., antidepressants, neuroleptics, benzodiazepines, and lithium) on data. In addition, emphasis was given to suicide as possible confounding factor. *P*-values less than 0.05 were deemed to be statistically significant.

Results
=======

Qualitative Observations
------------------------

### Glutamine Synthetase Immunostaining

#### Astrocytes

Glutamine synthetase -immunoreactive ACs were abundantly present in the cerebral cortex and the NAc. Their morphology was remarkably consistent. Astrocytic somata and processes were prominently stained for GS. In addition, an intense immunostaining was observed in the neuropil. Numerous blood vessels were surrounded by GS-immunoreactive AC endfeet.

#### Oligodendrocytes

Gray matter GS-immunoreactive OLs were easily identifiable based on their typical morphology. The immunoreaction was confined to the cell somata. Short processes were only infrequently immunolabeled. Immunopositive OLs were fairly uniformly distributed throughout prefrontal cerebral cortex. However, in the AiC and the NAc GS-expressing OLs were relatively rarely found. Therefore, we did not count them separately in the latter two brain regions. Examples for the immunolocalization of GS in ACs and OLs are given in **Figures [1A--I](#F1){ref-type="fig"}**. **Figure [1J](#F1){ref-type="fig"}** shows a control reaction.

![**Immunolocalization of GS in cortical and subcortical human brain glial cells in MDD, BD, and controls. (A)** GS-immunoreactive ACs and OLs (asterisk) in the pACC (control case). Bar = 20 μm. **(B)** GS-immunoreactive ACs and OLs (asterisks) in the pACC (MDD subject). Bar = 20 μm. **(C)** GS-immunoreactive ACs and OLs (asterisk) in the pACC (BD subject). Bar = 20 μm. **(D)** GS-immunoreactive ACs and OLs (asterisks) in the sACC (control case). Bar = 20 μm.**(E)** GS-expressing ACs and OLs (asterisk) in the sACC (MDD subject). Bar = 20 μm.**(F)** GS-expressing ACs and OLs (asterisk) in the DLPFC (BD subject). Bar = 20 μm. **(G)** GS-immunopositive ACs in the AiC (control case). Bar = 20 μm. **(H)** GS-expressing ACs in the NAc (control case). Bar = 24 μm. **(I)** GS-immunoreactive OLs (asterisks) in the pACC (control case). Bar = 20 μm. **(J)** Specificity control reaction. After preabsorption of the primary antiserum with recombinant GS protein no specific immunostaining is visible. Bar = 30 μm.](fncel-09-00273-g001){#F1}

### GFAP Immunostaining

In all cortical areas GFAP protein was expressed in a majority of ACs. Their distribution showed a laminar pattern. The highest package density of GFAP was found in layers I (where ACs abut at the pial surface of the brain, [@B53]) and II. In the NAc an even distribution of GFAP immunolabeled cell elements was observed. OLs did not express GFAP.

Quantitative Estimates
----------------------

We could replicate our own findings ([@B7]) as well as results previously published by others ([@B78]) that there is a higher density of GS-expressing cells in superficial cortical layers I--III than in deeper cortical layers IV--VI. It is therefore justified to count superficial and deeper layers separately.

In subjects with mood disorder significantly reduced numerical densities of GS immunoreactive ACs were found the DLPFC (left side, layers I--III, *p* = 0.029; *F* = 4.487 and right side, layers I--III; *p* = 0.046; *F* = 3.647), sACC (left side, layers I--III, *p* = 0.021; *F* = 4.304), AiC (left side, layers I--III, *p* = 0.002; *F* = 7.893; right side, layers I--III, *p* = 0.001; *F* = 9.789; ride side, layers IV--VI, *p* = 0.015; *F* = 5.136). No significant changes were detectable in the pACC and the NAc. All but one (DLPCC right side, layers I--III) significant changes survived Tukey's HSD *post hoc* tests. Notably, no significant alterations in the numerical densities of OLs were found. Results of the morphometric analyses are shown in **Figures [2](#F2){ref-type="fig"}**--**[6](#F6){ref-type="fig"}**.

![**Numerical densities of GS-expressing glial cells (ACs and OLs) in the DLPFC of subjects with MDD, BD, and controls.** Compared with controls the density of GS-expressing ACs is significantly reduced in MDD cases (AC left I--III, *p* = 0.029; AC right I--III, *p* = 0.046).](fncel-09-00273-g002){#F2}

![**Numerical densities of GS-expressing glial cells (ACs and OLs) in the pACC of subjects with MDD, BD, and controls.** No significant alterations were found in this brain region.](fncel-09-00273-g003){#F3}

![**Numerical densities of GS-expressing glial cells (ACs and OLs) in the sACC of subjects with MDD, BD, and controls.** Compared with controls the density of GS-expressing ACs is significantly reduced in MDD cases (AC left I--III, *p* = 0.021).](fncel-09-00273-g004){#F4}

![**Numerical densities of GS-expressing glial cells (ACs and OLs) in the AiC of subjects with MDD, BD, and controls.** Compared with controls the density of GS-expressing ACs is significantly reduced in MDD cases (AiC left I--III, *p* = 0.002; AiC right I--III, *p* = 0.001; AiC right IV--VI, *p* = 0.015).](fncel-09-00273-g005){#F5}

![**Numerical densities of GS-expressing glial cells (ACs and OLs) in the NAc of subjects with MDD, BD, and controls.** No significant alterations were found in this brain region.](fncel-09-00273-g006){#F6}

### MDD vs. controls

Compared with controls a significant reduction in the numerical densities of GS-immunopositive ACs was found in MDD in five of the 10 cortical and subcortical brain regions studied: DLPFC (left side, layers I--III, *p* = 0.024), sACC (left side, layers I--III, *p* = 0.018); AiC (left side, layers I--III; *p* = 0.002; right side, layers I--III; *p* = 0.001; *F* = 9.962; right side, layers IV--VI, *p* = 0.012).

### BD vs. controls

In BD cases the numerical densities of GS-expressing ACs and OLs did not significantly differ from those of controls.

### MDD vs. BD

Compared with BD cases subjects with MDD showed significantly decreased densities of GS-immunopositive ACs in the DLPFC (right side, layers I--III, *P* = 0.047), in the AiC (left side, layers I--III, *p* = 0.024; right side, layers IV.IV; *p* = 0.001).

### Impact of Completed Suicide on Cell Densities

Since there are reports showing that GS expression is altered in brains of suicide victims with and without mood disorder ([@B45]; [@B69]; [@B11]) we next analyzed the influence of the confounding factor "death by suicide" on the densities of GS immunoreactive ACs in the brain regions under study. For this purpose we divided MDD and BD cases into subgroups of suicide victims (MDD: *N* = 11; BD: *N* = 7) and depressed subjects who died of natural causes (MDD: *N* = 3; BD: *N* = 8). With regard to MDD cases in none of the brain regions there appeared significant differences in the densities of GS-expressing cells between depressed subjects dying by suicide and non-suicidal individuals with MDD. The same holds true for subjects with BD: Suicidal and non-suicidal BD cases did not significantly differ with regard to glial cell densities in any of the regions studied, as exemplified for the AiC in **Figure [7](#F7){ref-type="fig"}**. It should be emphasized, however, that the subgroup of non-suicidal subjects with MDD is too small (*N* = 3) to come to far-reaching conclusions from these data.

![**Numerical densities of GS-expressing glial cells in the AiC of suicide completers with MDD, non-suicide completers with MDD, suicide completers with BD, non-suicide completers with BD, and controls.** No significant alterations were found.](fncel-09-00273-g007){#F7}

### The Influence of Other Confounding Factors

Analysis of the potential confounding factors on the test results revealed no significant influence of age, gender, duration of disease, or psychotropic medication. Especially the lack of correlation between the age and the density of GS-expressing ACs is interesting, because [@B62] have hypothesized the glial pathology appears to apply mostly to younger and middle age subjects with MDD (\<60 years of age).

### Possible Influence of Hemispheric Asymmetry on GS Cell Distribution in Human Brain

There is evidence in the for structural, functional, and physiological asymmetries in the two hemispheres of human brain (comprehensively reviewed in [@B41]), which involve aspects of glutamate and GABA metabolism in health and mood disorder (MDD: [@B58]; [@B4]; [@B35]; BD: [@B35]; [@B84]). The latter might in part result from left--right hemispheric differences in the distribution of GS immunoreactivity ([@B11]), Unfortunately, knowledge about the catalytic activity and distribution of human brain GS comes mainly from studies of only one (namely the left) brain hemisphere ([@B17]; [@B61]; [@B53]). To exclude a possible left--right asymmetry of GS, we counted left and right hemispheres separately. No evidence was found for a significant left--right asymmetry, neither in controls, nor in subjects with affective disorder.

Discussion
==========

Major depression disorder and BD are serious mental illnesses with multifactorial pathophysiologic characteristics. The past years have witnessed a remarkable extension of our understanding of the neurobiology of affective disorders, adding the glutamatergic and the GABAergic hypotheses to "classical" monoaminergic theories of mood dysregulation ([@B25]; [@B72]; [@B18]; [@B28]; [@B39]; [@B57]; [@B67]). Besides other indicators of compromised amino acidergic neurotransmission in depression, two large meta-analyses of neuroimaging findings have demonstrated decreased levels of the Glx in adult MDD patients, whereas in the brains of BD patients increased, decreased, and unchanged glutamate and reduced glutamine levels have been measured ([@B85]; [@B33]; [@B47]). Moreover, the NMDA receptor antagonist ketamine has been shown in clinical trials to act as a rapid antidepressant in MDD (for recent considerations, see [@B26]). The acceptance of a crucial role of glutamate in the pathology of mental disorders entails the obligatory implication of glial cells ([@B3]). Being part of the glutamatergic tripartite synapse, intact ACs are central to a proper functioning of glutamatergic neurotransmission, and imbalances in the neuron-AC communication at the synaptic level might significantly contribute to affective disorders, such as mania and depression ([@B54]; [@B77]). The enzyme GS, which is highly expressed in, but in its expression not restricted to, ACs, is required to synthesize the non-toxic glutamine from the re-uptake of either glutamate or GABA. Besides, in human brain an immunologically and enzymatically very closely related "sister" enzyme of (GS-like protein) of unknown cellular localization was found ([@B14]), which shows altered expressions in schizophrenia and Alzheimer's disease ([@B17]; [@B16]). The possible implication of GS-like enzyme for mood disorders is unexplored, however. Keeping this in mind when designing this study, we morphometrically analyzed GS-immunoreactive glial cells located in various cortical and subcortical gray matter areas of subjects with MDD and BD, thereby counting, wherever possible, ACs and OLs separately. Significantly reduced densities of GS immunopositive ACs were found in the prefrontal areas DLPFC and sACC as well as in the AiC of subjects with MDD. Remarkably, the densities of GS-immunopositive OLs were normal in all regions studied, although a significant loss of perineuronal OLs was found in prefrontal cortex sublayers IIIa, b, and c in mood disorder by others ([@B82]). When carefully analyzing cortical GS-expressing OLs in mice, [@B75] found that the enzyme protein is mainly expressed in perineuronal OLs, with roughly half of them being GS-immunopositive. However, these GS-immunoreactive OLs lack plasmalemmal glutamate transporters GLAST and GLT-1, thus apparently being unable to participate in the glutamate-glutamine cycle. The reason why these cells even so express GS remains enigmatic, but is seemingly not directly related to glutamatergic synaptic neurotransmission (possibly playing a role in cellular ammonia clearance and/or certain metabolic support to the associating cortical neurons, [@B75]; [@B7]). Thus, our data clearly show a cell-type specific reduction in cortical GS expression in individuals with MDD, which cannot be revealed when analyzing total GS protein in brain samples with biochemical methods. Interestingly, we found no indication for altered densities of GS-expressing ACs in the NAc, although this brain region plays a central role in MDD ([@B77]) and has therefore been chosen as a target structure for deep brain stimulation in cases of therapy-resistant MMD ([@B12]). Although ACs play a critical role in controlling the excitability of NAc neurons via activation of glutamatergic receptors ([@B32]; [@B77]), their possible implication for "human" depression" yet is poorly explored. However, the number of ACs in the NAc was found to be unchanged in a developmental "toxic stress" model of depression ([@B70]).

Unlike in MDD, no alterations in the density of GS-expressing glial cells were found in BD cases. This is in agreement with earlier findings by [@B78], but in contrast to reduced GS expression in prefrontal area of BD subjects as reported by [@B19]. Two possible conclusions may be drawn from our data: either (1) glia associated-GS is normal, because GS does not play a prominent role in the pathophysiology of BD, and/or (2) GS expression was "normalized" (most probably up-regulated) by long-term treatment of the disease. Given the latter possibility, two putative factors might have increased GS expression in brains of BD subjects: administration of lithium ([@B42]) and treatment with antidepressants ([@B38]; [@B46]). Our calculations, however, did not reveal significant positive correlations of numerical densities of GS expressing glial cells and either of the aforementioned two factors. Hence we tend to believe that GS is not a major contributing factor to BD neuropathology. It should be stated, however, that disease-related alterations in the cerebral expression of GS do not always exert a direct influence on the glutamate--glutamine--GABA ratio. So, for example, a strong upregulation of GS protein was reported for the anterior cingulate cortex of female but not male individuals with schizophrenia ([@B52]), whereas no such gender-specific change in the Glx ratio was found in schizophrenia patients by MRS ([@B63]). Thus, further studies are clearly needed to learn more about the impact of GS on glutamate metabolites in the brain.

Limitations of the Study
------------------------

Since a major limitation of post-mortem studies is underpowered sample size, we have tried to increase the three cohorts (controls, *N* = 16; BD, *N* = 15, MDD, *N* = 14). A consequence from doing so is to accept the lack of data on the cumulative antidepressant exposure of some patients with MDD and BD. A further limitation of the this study is that, as in all immunocytochemistry-based morphometric studies, it cannot be said with ultimate certainty, whether the observed disease-related changes are due to glial cell loss, or to reduced intracellular expression of the protein (below the detection threshold of the method) in still existing cells, or both. Lastly, a limitation may arise from the fact that the decreased expression of GS protein does not necessarily mean reduced activity of the enzyme. Unfortunately, it is impossible to reveal the catalytic activity of the AC-located GS enzyme because of the lack of a specific enzyme histochemical method for GS.

Conclusion
==========

In MDD but not in BD there is a glia cell-type specific (astroglial) reduction of cortical GS protein expression, which might constitute a cellular correlate of lower cortical Glx levels reported for subjects with MDD in MSR studies.
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AC(s)

:   astrocyte(s)

Aic

:   anterior insular cortex

ANOVA

:   A single-factor analysis of variance

ATP

:   adenosine triphosphate

BD

:   bipolar disorder

CNS

:   Central Nervous System

DLPFC

:   dorso-lateral prefrontal cortex

GABA

:   γ-Aminobutyric acid

DSM-IV

:   Diagnostic and Statistical Manual of Mental Disorders IVth edition

GFAP

:   glial fibrillary acidic protein

Glx

:   glutamate-glutamine-GABA complex

GS

:   glutamine synthetase

MANOVA

:   Multivariate analysis of covariance

MDD

:   major depression disorder

MSR

:   Magnetic Resonance Spectroscopy

OL(s)

:   oligodendrocyte(s)

n.a.

:   not available

NAc

:   Nuc. Accumbens

pACC

:   pregenual anterior cingulate

PBS

:   Phosphate buffered saline
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:   subgenual anterior cingulate cortex
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